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Background: Colon cancer patients with the same stage show diverse clinical behavior due to tumor
heterogeneity. We aimed to discover distinct classes of tumors based on microarray expression patterns, to analyze
whether the molecular classification correlated with the histopathological stages or other clinical parameters and to
study differences in the survival.
Methods: Hierarchical clustering was performed for class discovery in 88 colon tumors (stages I to IV). Pathways
analysis and correlations between clinical parameters and our classification were analyzed. Tumor subtypes were
validated using an external set of 78 patients. A 167 gene signature associated to the main subtype was generated
using the 3-Nearest-Neighbor method. Coincidences with other prognostic predictors were assesed.
Results: Hierarchical clustering identified four robust tumor subtypes with biologically and clinically distinct
behavior. Stromal components (p< 0.001), nuclear β-catenin (p = 0.021), mucinous histology (p = 0.001),
microsatellite-instability (p = 0.039) and BRAF mutations (p< 0.001) were associated to this classification but it was
independent of Dukes stages (p = 0.646). Molecular subtypes were established from stage I. High-stroma-subtype
showed increased levels of genes and altered pathways distinctive of tumour-associated-stroma and components
of the extracellular matrix in contrast to Low-stroma-subtype. Mucinous-subtype was reflected by the increased
expression of trefoil factors and mucins as well as by a higher proportion of MSI and BRAF mutations. Tumor
subtypes were validated using an external set of 78 patients. A 167 gene signature associated to the Low-stroma-
subtype distinguished low risk patients from high risk patients in the external cohort (Dukes B and C:HR = 8.56(2.53-
29.01); Dukes B,C and D:HR = 1.87(1.07-3.25)). Eight different reported survival gene signatures segregated our
tumors into two groups the Low-stroma-subtype and the other tumor subtypes.
Conclusions: We have identified novel molecular subtypes in colon cancer with distinct biological and clinical
behavior that are established from the initiation of the tumor. Tumor microenvironment is important for the
classification and for the malignant power of the tumor. Differential gene sets and biological pathways characterize
each tumor subtype reflecting underlying mechanisms of carcinogenesis that may be used for the selection of
targeted therapeutic procedures. This classification may contribute to an improvement in the management of the
patients with CRC and to a more comprehensive prognosis.
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Colorectal cancer is one of the most common malignancies
in the western world and accounts for about 10% of all can-
cer deaths in both Europe and the USA. Traditionally, colo-
rectal cancer classification (Dukes, AJCC (American Joint
Committee on Cancer)) is based in the extent of the cancer:
depth of tumor invasion into the wall of the intestine, num-
ber of nearby affected lymph nodes and whether the cancer
has metastasized to other organs of the body. Surgery is
curative for a big proportion of patients at early stages, but is
not enough for many patients at advanced stages. Most of
these patients need adjuvant chemotherapy in order to avoid
relapse or to increase survival. Unfortunately, only a small
portion of them shows an objective response to chemother-
apy, becoming problematic to correctly predict patients’ clin-
ical outcome [1]. Microarray gene expression profiling is a
powerful tool for the identification of prognostic gene signa-
tures. Supervised analysis of gene expression has been used
to discover gene signatures to identify patients at risk of re-
currence in colon cancer [2-8]. Recently two extensively vali-
dated gene signatures have been reported Oncotype-DX and
ColoPrint [9,10]. A different approach is to use unsupervised
analysis. Clustering methods group together samples with
similar expression profiles. With this strategy, new subtypes
of tumors can emerge or the existing classification may be
redefined with the result of more uniform groups of tumors.
Molecular homogeneity may be essential in order to identify
specific biological pathways affected, to discover precise drug
targets in each subgroup or to obtain individual survival clas-
sifiers. Previous attempts to subdivide colon tumors into
sub-classes or to correlate gene expression to Dukes stages
using unsupervised analysis haven’t been conclusive. Some
authors were able to correctly classify normal colon, Dukes B
and C but not Dukes A and D and no new subgroups were
identified [11]. Others were able to classify in one group nor-
mal tissue with Dukes A, in another cluster B with C, and D
clustered separately [12]. Other authors were unable to find
differences between stages B, C and D [13]. Some reports
found differences between normal and tumor tissue and
genes differentially expressed between metastatic and non-
metastatic samples [14-16] or segregate normal tissue from
primary carcinomas and from liver metastasis and carcino-
matoses [14,17]. Other authors using class comparison be-
tween Dukes A and D identified a gene signature that could
be used for the classification of low- and high-risk patients in
Dukes B and C [7]. Another interesting approach described
the identification of a gene expression profile generated from
an experimental model of colon cancer metastasis that was
able to predict cancer recurrence in patients with colon can-
cer [18]. Other authors reported that epidermal growth fac-
tor receptor pathway was up-regulated in metachronous
liver metastasis while angiogenesis was up-regulated in syn-
chronous liver metastasis [19]. Unfortunately, even if there is
an ample selection of gene signatures reported in theliterature, almost none of them have reached the clinical
practice. There is a need of prognostic and predictive factors
to provide authoritative information for medical decisions in
routine clinical practice. Our study was mainly aimed to ob-
tain more homogeneous groups of tumors in colorectal
adenocarcinomas hypothesizing that discovering molecularly
more uniform groups of tumors, would likely discriminate
patients with different clinical outcomes, as well. In addition
understanding the biological pathways underlying each




Patients from all stages were selected, keeping approxi-
mately equal proportion of each stage (24 Dukes A or
AJCC (6 edition) stage I; 26 B or II; 19 C or III and 19 D or
IV)). Tumor samples were taken from the Bank of Tumors
of the Hospital Clinico San Carlos between 2001 and 2006.
The Bank of Tumors follows the rules established by the
hospital including the patient consent approved by the Eth-
ical Committee of the Hospital Clinico San Carlos.
Histological analysis of tumor samples
Many reports have shown the importance of tumor asso-
ciated stroma in the development of cancer; therefore for
our study we did not consider to do laser microdissection
to get just the transformed epithelial cells. We wanted to
analyze both, tumor cells from the malignant epithelia and
the altered surrounding stroma. We took a representative
fragment of the complete tumor and we carried out a very
detailed pathological analysis of the frozen tumor frag-
ments used to extract the RNA and of the corresponding
paraffins of the tumor. Only samples with more than 80%
of tumor component were included, considering tumor
stroma as part of the tumor component.
RNA extraction and quality control
RNA was extracted directly from the frozen samples using
TRIZOL (Invitrogen, Carlsbad, CA) and a homogenizer
(Ultraturrax T8-S8N-5 G Rose Scientific Ltd, Canada).
Afterwards, RNA was treated with DNAse using RNeasy
Microkit (Qiagen GmbH, Germany). RNA quality was mea-
sured with Agilent Bioanalyzer 2100 (Agilent technologies, Palo
Alto U.S.A) and only good quality samples, RIN (RNA Integrity
Number) [20,21] higher than 7.5, were selected for the analysis.
Microarray analysis
Agilent G4112 microarrays were used to analyze gene expres-
sion in 88 colon tumors and 7 normal colon tissues. A refer-
ence RNA preparation (pool of normal colon tissue RNAs
obtained from 68 individuals) was used for double
hybridization: tumor-Cy5/pool-Cy3, normal-Cy5/pool-Cy3.
Agilent recommended protocols were followed. Fluorescence
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microarray scanner and Feature Extraction software. Quality
Control Report was carried out to discard the microarrays
that did not fulfill good quality criteria. From the original
44 K features microarray, a total of 28462 spots without flags
in 90% of the microarrays were used. Only probes that were
significantly (p< 0.01) up or down regulated vs. the reference
pool, in at least 7 samples (considering the 7 normal tissue
samples as the smallest group) were selected to obtain 17392
spots. Probes with the same gene identification were averaged
to obtain a total of 14764 genes. For classification purposes
we chose the genes that showed higher variations between
tumors, selecting the genes that in more than 7 samples
had at least a 2.5-fold change from the gene median value,
resulting 1722 genes that were used for the unsupervised
analysis of the 89 samples (tumor CT102 was replicated).
Cluster reproducibility was measured by the robustness
index (R-index) and by the discrepancy index (D-index);
[22] analyses were performed using BRB-ArrayTools devel-
oped by Dr. Richard Simon and BRB-ArrayTools Development
Team. Transcript Profiling: [ArrayExpress E-TABM-723].
Functional analysis of KEGG pathways
A functional analysis of KEGG pathways using class com-
parison tools (Goeman’s global, LS, KS Efron. Tibshirani’s
tests) was carried out to find differentially affected pathways
between the four tumor subtypes. 164 gene sets were stud-
ied and the threshold used was set at p=0.005. Multiple
comparisons were corrected using resampling and gene
permutations. Since Goeman's method tests the null hy-
pothesis that no genes within a given gene set are differen-
tially expressed and LS test, KS test and Efron-Tibshirani's
methods, test the hypothesis whether the average degree of
differentially expression is greater than expected from a
random sample of genes (BRB-ArrayTools), KEGG path-
ways selected had to be significant at least in two tests:
Goeman’s test and any of the other three tests carried out.
Tissue microarrays (TMA), IHC and mutation analysis
Tissue microarrays were assembled as in [23] for immuno-
logical analysis of β-catenin (clone17c2 Novocastra Laborator-
ies Ltd. Newcastle upon Tyne, UK), M30 (M30 CytoDEATH
Roche Diagnostics GmbHMannheim Germany) for apoptosis
and KI67 (clone M1B1, Dako, Glostrup, Denmmark) for pro-
liferation. Presence of mutations in KRAS, BRAF and PI3K as
well as microsatellite instability (MSI) were also assessed. See
Additional file 1: Supplementary Information for more infor-
mation about the protocols followed for antibody staining and
analysis of MSI and gene mutations.
Identification of tumor subgroups in an independent data
set
Eschrich et al. [2] data set was used as an external patient
collection. Data was combined using the method publishedby Hu et al. [24]. The genes that had the same UniGene
Cluster ID were averaged and the genes that did not have a
UniGene Cluster ID were eliminated from our data set
resulting 11017 genes out of the 14764 genes and 96 sam-
ples (normal and tumor samples). Eschrich data set consists
of 78 samples (23B, 22 C, 30D and 3 adenomas) and 32208
normalized transcripts. Spots without IDs or with more
than 25% missing values were eliminated and spots with
the same UniGene Cluster ID were averaged. Genes with
90% of data were selected to obtain a total of 9229 genes.
Combination of data sets: both data sets were combined
using the software “Distance Weighted Discrimination”
(https://genome.unc.edu/pubsup/dwd/) to obtain a collec-
tion of 174 samples (166 tumors) and 5319 common genes.
Classification of the external data set: A Nearest Cen-
troid predictor was built in our data set including only genes
differentially expressed between classes at a p< 0.001.
LOOCV (Leave-One-Out Cross-Validation) and 100 ran-
dom permutations were used to compute miss-classification
rate. This predictor was subsequently used to classify the ex-
ternal samples into the four novel clusters. Hierarchical
clustering: To analyze whether the external patient’s set
clustered with our patients in the same tumor subtypes, Cen-
tered Pearson correlation and average-linkage-hierarchical
clustering of the combined set (159 tumor samples excluding
samples from cluster-5, normal tissues and adenomas) was
carried out using the 461 common genes between both data
sets out of the 1722 originally selected genes.
Generation of a low-stroma-subtype predictor
Eschrich samples were classified as belonging to the Low-
stroma-subtype or belonging to the other tumor subtypes
using the K-nearest-neighbor, K= 3 (KNN3) prediction
method. A predictor was generated in our data set using
the 461 common genes between both data sets out of the
1722 originally selected genes. Genes included in the pre-
dictor were differentially expressed between classes at a
p< 0.001. LOOCV and 100 random permutations were
used to compute miss-classification rate.
Statistical analysis and correlations with clinical
parameters and survival analysis
Qualitative variables are given with their frequency distri-
bution. Quantitative variables are given with their mean
and standard deviation (SD). Means were compared with
Kruskal-Wallis test. Proportions were compared by the
chi square test for independent groups. Survival functions
were estimated by the actuarial method. Cumulative risks
over time and their corresponding standard errors (SE)
are provided along with the number of patients at risk (n).
Likelihood exact test was used to compare survival func-
tions for the different subgroups. A Cox's proportional
hazards regression model was fitted. Significance was
taken as a drop in the likelihood estimator of the models
Figure 1 Hierarchical clustering of the colon tumor samples
and the 1722 selected genes A) Classification of the 89 (sample
CT102 is replicated) tumor samples in four main clusters. Yellow
shadow: Cluster-1, Low-stroma-subtype; green: Cluster-2,
Immunoglobulin-related-subtype; red: Cluster-3, High-stroma-
subtype; blue: Cluster-4, Mucinous-subtype; and brown: Cluster-5,
unclassified samples. Dukes’ stages are specified below the tree. B)
Each column in the heatmap represents one sample and each row
represents one gene. The relative levels of gene expression within
each sample against the reference pool are illustrated according to
the color scale bar (4 fold induction (red); -4 fold inhibition (blue)).
The principal sections of the graph that distinguish between clusters
are indicated with a color bar on the right. The green bar localizes
gene 270 to gene 523, a group of 253 genes with low expression in
cluster 1 and high expression in cluster 3; the red bar corresponds
to genes 524 to 664 a group of 140 genes, whose expression is
lower in cluster 1. Blue bar localizes genes 997 to 1102 a group of
105 genes with a higher expression in cluster 4 compared to 3.
Yellow bar localizes genes from 1247 to 1352 a group of 105 genes
specific for cluster 2 (see Supplemental data for the list of the 1722
genes).
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dence interval (95%CI) are provided in the results. In each
hypothesis contrast the assumption of rate proportionality
was verified. In all hypothesis contrasts (survival analysis
and clinical parameters correlations) the null hypothesis of
no difference was rejected with a type I or α-error of less
than 0.05. Correction of p-values was not performed. Stat-
istical analysis was performed with SPSS 15.0 for Win-
dows (SPSS Inc., Chicago, USA).
Results
Identification of tumor subtypes by hierarchical clustering
Centered Pearson correlation and average-linkage-hierarchical
clustering with the 1722 selected genes was used to group
both tumors and genes. The 89 tumor samples (tumor CT102
is duplicated) were arranged primary in two main groups
(Figure 1A). The first group contains just one class, cluster-1,
with 36 tumors (40% of the total number of samples). The
second main group holds the rest of the tumors that were
classified in three smaller reproducible subgroups, clusters-2, -
3 and −4 containing 12, 22 and 14 tumors respectively
(Figure 1A). The robustness and reproducibility of the four
new clusters was high, mainly for clusters-1, -3 and −4 with
robustness close to 0.9 and a low number of samples additions
or omissions. Cluster-2 was the weakest of the four clusters
with a robustness of 0.75 (Table 1). Hierarchical clustering
identified a fifth cluster with five elements in it and a lower ro-
bustness; we did not regard this 5th cluster as a group consid-
ering those samples as unclassified tumors.
The dendrogram of the 89 tumor samples and the 1722
selected genes is shown in Figure 1B. The principal sec-
tions of the graph that distinguish between clusters are
indicated with a color bar on the right (Additional file 2:
List of 1722 genes see supplementary material). The green
Table 2 Patients characteristics
Patients (n) Percentage
Sex Men 43 48.9%
Women 45 51.1%
Age (years) Mean (min-max) 70.9 (25–93)
RIN Mean (min-max) 8.9 (7.5-10)




MSS/MSI MSS 79 89.8%
MSI 9 10.2%
Location Ascending C. 33 37.5%
Sigmoid 32 36.4%
Rectum 14 15.9%
Descending C. 3 3.4%
Transverse C. 6 6.8%
Mut. PI3K Exon 9 12 13.6%
Exon 20 8 9.1%
Wild Type 68 77.3%
Mut. B-Raf Mutated 8 9.1%
Wild Type 80 90.9%
Mut. K-ras Codon 12 28 31.8%
Codon 13 6 6.8%
Wild Type 54 61.4%
Histologic grade Undifferentiated 1 1.1%
Poorly diff. 5 5.7%
Moderately diff. 51 58.0%
Well diff. 31 35.2%
Histologic subtypes Conventional 78 88.64%
Mucinous 10 11.36%
Tumoral margin Expansive 16 18.18%
Infiltrative 61 69.32%
Mixed 11 12.50%
Vascular invasion Yes 33 37.50%
No 55 62.50%
Perineural invasion Yes 8 9.09%
No 80 90.91%




RIN: RNA integrity factor.
Table 1 Cluster-specific reproducibility
Cluster Samples (n) Robustness Omissions Additions
Cluster 1 36 0.90 2.54 1.78
Cluster 2 12 0.75 2.24 4.98
Cluster 3 22 0.87 1.78 2.34
Cluster 4 14 0.89 0.92 0.58
Cluster 5 5 0.65 1.29 1.56
1000 perturbations were used; SD= 0.439. Overall reproducibility:
R-Index = 0.88; D Index = 10.004.
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sion in cluster-1 and highest expression in cluster-3 and is
enriched in genes that have been reported to be specifically
activated in tumor-associated stroma and molecules impli-
cated in extracellular matrix remodeling and cell migra-
tion. Since these two clusters were mainly characterized by
differences in the abundance of stromal genes, cluster-1
and cluster-3 were defined as the Low-stroma-subtype and
the High-stroma-subtype respectively. The red bar loca-
lizes genes with lower levels in cluster-1 but their expres-
sion is not higher in cluster-3 than in clusters-2 and −4.
Distinctive genes of this section are metallothioneins,
metallopeptidases and SPP1. Blue bar show the location of
genes up-regulated in Cluster-4. These are molecules typ-
ically associated to the mucinous type of adenocarcinomas
like trefoil factors and mucins, for these characteristics
cluster-4 was defined as the Mucinous-subtype. Yellow bar
localizes the genes up-regulated in cluster-2. This cluster is
mainly characterized by a collection of immunoglobulin-
related molecules, for this reason cluster-2 was named as
the Immunoglobulin-related-subtype.
Functional analysis of KEGG pathways
KEGG pathways analysis sustains the implication of the
tumor microenvironment in the identified tumor subgroups
(see Additional file 1: Table S1 for the list of deregulated
KEGG pathways). Pathways corresponding to cell commu-
nication, ECM-receptor interaction, Focal adhesion and
Cell adhesion molecules showed differences between clus-
ters; elements of these pathways showed significantly lower
values in the Low-stroma-subtype than in the other tumor
subtypes. Other significant deregulated pathways showing
differences among clusters were WNTand TGF pathways.
Correlations of tumor subtypes with clinical parameters
The Patients’ characteristics are summarized in Table 2.
Correlation analysis was performed to find associations
between the four novel clusters and clinical parameters
(Table 3 and Additional file 1: Table S2). Dukes stages did
not show any association (p= 0.646) with the identified
tumor subgroups (Figure 1A, Table 3). Parameters that
showed a clear correlation with the identified tumor sub-
types were: proportion of stroma in the tumors, mucinous
Table 3 Correlation of tumor subgroups with clinical parameters
Parameter Cluster-1 (n= 35) Cluster-2 (n = 12) Cluster-3 (n= 22) Cluster-4 (n = 14) p-global
Microsatellite instability MSS 33 11 21 9 0.039LR,a
MSI 2 1 1 5
Histologic subtypes Conventional 34 12 21 8 0.001LR,b
Mucinous 1 0 1 6
% Stroma content frozen sample Mean 11.2 18.8 23.4 18.9 <0.001KW,c
SD 6.0 10.3 10.5 14.8
% Stroma Paraffin Mean 12.6 17.1 18.9 16.8 0.047KW,d
SD 6.0 9.9 8.6 14.2
nuclear β-Catenin (IHC) LOW 21 9 11 12 0.021LR,e
MEDIUM 4 0 6 1
HIGH 10 2 5 0
BRAF mutations (V600E) Mutated 0 1 1 6 <0.001LR,f
WT 35 11 21 8
Dukes Stage A 9 5 4 4 0.646LR
B 9 3 6 7
C 8 2 6 2
D 9 2 6 1
LR: Likelihood Ratio. KW: Kruskal Wallis. Pair wise comparisons: a: C4 6¼C1 (0.015); C4 6¼C3 (0.024); b: C4 6¼C1 (0.001); C2 6¼C4 (0.017); C4 6¼C3 (0.008); c: C1 6¼C4
(0.013); C1 6¼C2 (0.020); C1 6¼C3 (< 0.001); d: C1 6¼C3 (0.005); e: C1 6¼C4 (0.020); C2 6¼C3 (0.047); C3 6¼C4 (0.014); f: C4 6¼C1 (<0.001); C4 6¼C2 (<0.081); C4 6¼C3
(0.008); Frozen stroma vs paraffin ICC of 0.781 (IC95% 0.681-0.852) p< 0.001.
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and the V600E BRAF mutation. Proportion of tumor
stroma in the frozen fragments and in the corresponding
paraffin blocks were compared and no differences were
found (Intraclass Correlation-ICC=0.781 (IC95% (0.681-
0.852) p< 0.001). Amount of stroma was always the lowest
in cluster-1 and the highest in cluster-3; differences were sig-
nificant between these two clusters in both, frozen samples
(p< 0.001) and paraffins (p=0.005). Tumors in cluster-2
had similar amount of stroma than tumors in cluster-4. The
quantity of stroma was significantly lower in cluster-1
related to cluster-2 (p=0.02) and cluster-4 (p=0.013) in the
frozen samples. Mucinous histology was correlated signifi-
cantly with this classification (p=0.001). Pair wise compari-
sons showed that there was a significant association of the
mucinous histology, the MSI tumors and B-Raf mutations
to cluster-4 (Table 3). Nuclear β-catenin was also associated
with the clusters (Table 3; Figure 2). Pair wise comparisons
showed an increased proportion of epithelial cells with nu-
clear β-catenin in cluster-1 and −3 and a low proportion in
cluster-2 and −4. The presence of mutations in K-Ras
(codons 12/13) and PI3K (exons 9/20), proliferation (Ki67),
apoptosis (M30) as well as other histological parameters
did not show association with the molecular subtypes (see
Additional file 1: Table S2 for all parameters studied).
Recognition of tumor subtypes in an external clinical cohort
To classify Eschrich samples into the four novel clusters,
a classifier of 1039 genes was generated using the 5319common genes between both data sets and the Nearest
Centroid method (85% correct classification). After-
wards, unsupervised analysis of the combined set of 159
tumor samples was carried out. Hierarchical clustering,
using 461 genes, associated Eschrich’s samples classified
as Low-stroma subtype with our Low-stroma subtype
samples; Eschrich’s samples classified as High-stroma-
subtype with our High-stroma-subtype samples and his
tumors in the Mucinous-subtype with our samples in
Mucinous-subtype. Samples of the immunoglobulin
related subtype did not show a good association (see
Additional file 3: Figure S1). We also used other pre-
diction methods like K-Nearest-Neighbor, (K = 1 and
K= 3) and Diagonal Linear Discriminant, obtaining
similar results (not shown).Differences in survival time between the identified
tumors subtypes
Our set of patients was too heterogeneous to analyze
survival since it was mainly aimed to obtaining a com-
prehensive classification of colon cancer. From the
total of 88 patients, 26 did not had at least 36 months
of following up and other 23 patients were under dif-
ferent treatment schemes. Among the 39 untreated
patients there were just one death and four relapses.
Under these circumstances, the number of events was
not enough to obtain reliable results in the survival
analysis.
Figure 2 Immunohistochemistry with β-catenin antibody of tissue microarrays 200X amplification A, C and E; 400X amplification B,D
and F. Sample from tumor CT5 corresponding to Low-stroma-subtype (A,B); Sample from tumor CT42 corresponding to High-stroma-subtype (C,
D); sample from tumor CT103 corresponding to Mucinous-subtype (E,F). Note nuclear staining of β-catenin of CT5 and CT42 in contrast to
membrane β-catenin staining of CT103.
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low-stroma-subtype
To analyze differences in survival of the novel clusters,
first we took advantage of the survival predictors already
published. We analyzed whether Eschrich et al. [2] 43
genes survival predictor recognized specifically any of our
tumor subtypes. Hierarchical clustering of our 84 tumor
samples (excluding the samples from cluster-5), using the
17 common genes out of the 43 genes predictor, segre-
gated the samples into two clusters, the first was com-
posed mainly of tumors of the Low-stroma-subtype and
the second was composed of tumors of the other subtypes.
We also used the predictors of Garman et al. [8] Wang
et al. [3]; Lin et al. [4]; Jorissen et al. [7]; Smith et al. [18];
O'Connell et al. (Oncotype-DX) [9] and of Salazar et al.
(Coloprint) [10] obtaining similar results (Figure 3). How-
ever, other reported predictors such as Barrier et al. [5]
and Arango et al. [6] were unable to specifically recognize
any of our molecular subtypes (not shown).
The external patients classified as belonging to the low-
stroma-subtype showed better survival
Since Eschrich’s and other published predictors mainly
segregated the samples of the Low-stroma-subtype, next
step was to address whether our Low-stroma-subtype
predictor was able to identify in Eschrich’s data set, the
patients with good prognosis. Using the KNN3 classifica-
tion method and the 461 common genes between bothdata sets out of the 1722 selected genes, a predictor of
167 genes was generated (see Additional file 4: supple-
mental information for the list of 167 genes); 96% of cor-
rect classification was obtained (see Additional file 1:
Table S3 for classification performance). Kaplan-Meier
overall survival analysis of Eschrich’s patients classified
as belonging to the Low-stroma-subtype showed better
survival than the patients belonging to the other tumor
subtypes. Low-stroma-subtype patients showed better
survival when analyzing both, stages B and C only
(Figure 4A) and stages B, C and D (Figure 4B). We also
used the Nearest Centroid method finding similar results
(not shown).Coincidence among predictors
Usually there is a minimal overlap among reported high
risk gene signatures [25]. Our Low-stroma-subtype pre-
dictor showed some overlapping (12 genes in common)
with Jorissen et al. [7] predictor, two genes in common
with Eschrich et al. [2] and with Oncotype-DX [9] predic-
tors; one gene in common with the predictors of Garman
et al. [8] Wang et al. [3] and ColoPrint [10]. There were
no genes in common with Lin et al. [4] and with Smith
et al. [18] predictors (see Additional file 1: Table S4 for the
list of overlapping genes). Even though there was little or
none overlapping, all these eight reported predictors
recognized the tumors of the Low-stroma-subtype.
Figure 3 (See legend on next page.)
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Figure 3 Hierarchical clustering of our 84 tumor samples A) using the 17 genes that coincides in both sets out of the total of 43 genes
predictor of Eschrich et al.; B) using 37 genes out of the 50 genes predictor of Garman et al.; C) using 11 of the 23 genes of the predictor of
Wang et al.; D) using 17 of the 22 genes of the predictor of Lin YH et al.; E) using 115 of the 128 genes of the predictor of Jorissen RN et al.; F)
using 22 of the 34 genes of the predictor of Smith JJ et al.; G) using 6 of the 7 genes of the Oncotype-DX predictor; H) using 17 of the 18 genes
of the ColoPrint predictor. Blue line: tumors belonging to cluster-1 (Low-stroma-subtype). Black line: tumors from clusters-2, -3 and −4. Note that
almost all samples from the Low-stroma-subtype stay together in one group.
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A general approach to find prognostic markers in colon
cancer is using supervised analysis of gene expression. Class
comparison between patients with good and bad prognosis
has been carried out, and gene signatures that discriminate
between high and low risk patients have been reported [2-
10]. In this study, we have used a different strategy, hy-
pothesizing that the identification of distinct molecular
tumor subtypes would likely discriminate patients with dif-
ferent clinical outcomes, as well. In addition understanding
the biological pathways underlying each tumor subtype
would likely help to find the appropriate treatment scheme.
We report a molecular classification of colon adeno-
carcinomas in four novel tumor subtypes identified by
unsupervised analysis of gene expression. Tumor-
associated-stroma was clearly associated with this clas-
sification characterizing a Low-stroma-subtype and a
High-stroma-subtype. Mucinous histology, MSI, BRAF
mutations as well as lower levels of nuclear β-catenin
characterize the Mucinous-subtype. Tumor subtypes
were independent of the histopathological stages. Lack
of association with the histopathological staging is im-
portant, because it implies that tumor subtypes are
established since initial stages of the tumor, conse-
quently contributing to the selection of the patients at
early stages. Additionally, explains why many studies
were unable to reliably associate molecular classification
to Dukes stages [11,12,14,17]. The nature of the genes
expressed in each cluster and the biological pathways
affected supported the association of the molecular and
pathological parameters with the tumor subgroups. Low-
stroma-subtype, High-stroma-subtype and Mucinous-
subtype were robust, associated to biological characteristics
and validated in an external patient set. The combination
of two different microarray studies in one data set is chal-
lenging; many of the important genes in each data set may
be lost in the merged spreadsheet. Even though, when we
combined our data set with the external data set we still
kept important features in the combined data set. The
novel molecular subtypes were also identified in the exter-
nal data set (at least three of the four clusters).
Relevant reports identified stroma gene signatures asso-
ciated to survival in diffuse large-B-cell lymphoma [26] and
in breast cancer [27] reflecting the importance of tumormicroenvironment in the aggressive progression of the
disease [28]. Moreover a report in colon cancer showed
that the presence of a high amount of stroma, predicts
worse survival for stage I-II colon cancer patients [29].
Stroma was highly associated to our molecular classifica-
tion. Genes corresponding to pathways related to cell com-
munication, ECM-receptor interaction, Focal adhesion and
CAMs were down-regulated in the Low-stroma-subtype
and up-regulated in the High-stroma-subtype and in the
Mucinous-subtype. High-stroma-subtype had the highest
percentage of stroma in the tumors and the highest level of
stromal components. Mucinous-subtype also had high
levels of stroma associated genes and the proportion of
stroma was not significantly lower than in the High-
stroma-subtype. Although clusters-3 and −4 share similar
expression patterns of some of these stromal genes, there
are other important genes that clearly are different between
these two subtypes, genes characteristic of goblet cells, tre-
foil factors and mucins, as well as other genes like REGIV,
COX2 or CD55 are specifically up-regulated in cluster-4 or
Mucinous-subtype.
Microenvironment is important for tumor development
and more interestingly may be the target of novel treatments.
In this line, promising studies are underway. Although initial
studies using antibodies against activated fibroblast proteins,
like FAP, did not obtain objective tumor responses [30]. New
developments are taking advantage of the enzymatic activity
of FAP. With this strategy, a prodrug is administrated in an
inactive form that is proteolytically activated by the FAP
present in cancer activated fibroblasts localized in tumor
microenvironment. Once activated, the drug targets any cell
contained in the tumor [30,31]. Other therapies anti-stroma
under development target integrins-extracellular membrane
interactions [32,33] or target tumor stroma using T cells [34]
or human mesenchymal stem cells [35,36]. Consequently is
an active field of research and the identification of a high
stroma subtype group of patients may be essential to obtain
benefit from these treatments, administrating anti-stroma
therapies just to this group of patients.
Since our survival results showed that Low-stroma-
subtype identified lower risk patients and High-stroma-
subtype and Mucinous-subtype identified higher risk
patients, we contradict many reports indicating that MSI
tumors have better clinical outcome than MSS/L tumors
Figure 4 Kaplan-Meier overall survival analysis of Eschrich patients. A: (Dukes B and C); B: (Dukes B, C and D) classified as belonging to the
Low-stroma-subtype or belonging to the other tumor subtypes using the 167 genes Low-stroma-subtype predictor. Number of patients classified
in each class, hazard ratio and p values are indicated.
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tant factors usually found in poor prognostic tumors;
a) mucinous tumors have worse clinical outcome and in
our study mucinous and MSI tumors clustered together;
b) high levels of SPP1, FAP, GREMLIN1, CD55 or REGIVamong others have been reported to be associated with
cancer invasion, metastasis and poor prognostic in colon
cancer [39-45]. These genes are up-regulated in clusters-
3 and −4; c) the increased levels of TFF2 and MUC1,
characteristic of the Mucinous-subtype, have also been
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mutations have been shown as a worse prognostic fac-
tor [47,48]. Four out of the five MSI tumors in the
Mucinous-subtype harbor BRAF mutations. For all there
reasons, consequently, we could expect that patients of
High-stroma-subtype and Mucinous-subtype had a worse
clinical outcome.
The largest cluster was the Low-stroma-subtype and
shows key clinical properties that specially distinguish this
subtype from the other tumor subtypes. First, a 167 gene
signature associated to this group of tumors distinguished
low risk patients in an external clinical cohort. Second,
eight different reported gene signatures including the ex-
tensively validated Oncotype-DX and ColoPrint [2-4,7-
10,18], classified the Low-stroma-subtype patients in one
group and the other tumor subtypes in a second group.
Comparing microarray analysis across different studies and
platforms is challenging. In general there is little or none
overlapping among different gene signatures. In our study
we found that eight different reported survival predictors
and our 167 genes Low-stroma-subtype predictor, with al-
most no overlap among them, recognized the same group
of patients in our data, the Low-stroma-subtype. Further-
more, our 167 genes Low-stroma-subtype predictor was
able to identify in the external data set the patients with
better clinical outcome. What is important and relevant for
the application to the clinics is recognizing the same type
of patients, not to demonstrate overlapping among different
gene lists. This coincidence is important to confirm the po-
tential of microarray gene expression for the identification
of low risk patients. Nevertheless, it should be remarked
that survival outcomes have not been confirmed with our
own survival data and in the setting of a multivariable ana-
lysis. A higher sample size of homogeneous groups of
patients will be necessary to establish the prognostic value
of this molecular classification.
Conclusions
With these findings, we propose a colon cancer classifica-
tion in intrinsic molecular subtypes based on expression
patterns. The novel colon tumor subtypes are associated to
important clinicopathological features and show different
survival times, but are not correlated to the histopatho-
logical stages. Tumor subtypes are established from initial
tumor stages and validated in an external clinical cohort.
Tumor microenvironment is important for the classification
and for the malignant power of the tumor. Differential gene
sets and biological pathways characterize each tumor sub-
type reflecting underlying mechanisms of carcinogenesis
that may be used for the selection of targeted therapeutic
procedures. The novel molecular classification reported in
this study, may contribute to an improvement in the man-
agement of the patients with colorectal carcinoma and to a
more comprehensive prognosis.Additional files
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